Actively Recruiting
Phase 1b Study Assessing Safety and Pharmacokinetics of Oral Tacabrutideg in Adults With Chronic Spontaneous Urticaria and Healthy Volunteers
Led by BeOne Medicines · Updated on 2026-09-09
58
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of tacabrutideg in adults with chronic spontaneous urticaria CSU and in healthy participants. The study aims to better understand how the drug behaves and is tolerated in both affected individuals and healthy volunteers. Participants with CSU will be assigned to sequential groups receiving increasing doses of tacabrutideg. Those with CSU will first receive a matching placebo orally for 28 days before crossing over to tacabrutideg. Healthy participants will also receive increasing doses of tacabrutideg in sequential groups. The drug and placebo are administered orally, and dosing schedules vary by cohort. Throughout the study, participants will be monitored for adverse events and undergo pharmacokinetic assessments up to approximately 10 weeks. Those with CSU will have their urticaria symptoms tracked using various scoring systems, including the Urticaria Activity Score and Itch Severity Score, for up to 3 months. Researchers will also measure protein levels related to the disease. Safety, tolerability, and drug behavior will be closely watched during the treatment periods, which can last up to about 4 months for CSU participants and 6 weeks for healthy volunteers.
CONDITIONS
Brief Title
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here